Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs

by Zacks Equity Research

Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.

Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod

by Zacks Equity Research

Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

by Zacks Equity Research

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

by Zacks Equity Research

Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

by Zacks Equity Research

Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.

Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

by Zacks Equity Research

Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.

The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic

by Zacks Equity Research

Roche, Wells Fargo, General Aerospace and Key Tronic are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Roche, Wells Fargo & GE Aerospace

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Key Tronic Corporation (KTCC).

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

by Zacks Equity Research

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

by Zacks Equity Research

Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

by Kinjel Shah

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.

Regeneron (REGN) Announces Positive Data on Oncology Candidate

by Zacks Equity Research

Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More

by Kinjel Shah

AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.

Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

by Zacks Equity Research

Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen

by Zacks Equity Research

Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.

Sundeep Ganoria headshot

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

by Sundeep Ganoria

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

by Zacks Equity Research

Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

by Zacks Equity Research

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

by Zacks Equity Research

Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

by Zacks Equity Research

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.